

H1 2024 HIGHLIGHTS



“Our strategic progress was illustrated by strong results in the first half, and we are well placed to deliver continued attractive growth over the medium term.”


David Loew
Chief Executive Officer

**FY 2024 GUIDANCE
UPGRADED**

**Total sales growth
greater than 7.0% (at CER)**

**Core operating margin
greater than 30.0%
of total sales**

TOTAL SALES




■ Oncology
■ Rare Disease
■ Neuroscience

GEOGRAPHIC BREAKDOWN

H1 2024 TOTAL SALES BY REGION

33% North America **39%** Europe **28%** Rest of World



ONCOLOGY +6%



RARE DISEASE +84%



NEUROSCIENCE +13%



PIPELINE UPDATE

- In-licensing of tovorafenib outside the U.S.
- FDA approvals: Onivyde - first-line pancreatic cancer, Iqirvo – second-line primary biliary cholangitis
- Cabometyx opportunity in advanced neuroendocrine tumors
- Preclinical transactions across Oncology & Neuroscience
- ELSPIRE trial : potential to expand the opportunity for Iqirvo

Core operating income
€538m

Free cash flow
€393m

Core operating margin
32.4%

Core earnings per share¹
€4.78

For further information on Ipsen's H1 2024 sales update and definitions of financial indicators, please refer to the press release at:

Craig Marks

Vice President, Investor Relations
+44 7584 349 193
craig.marks@ipsen.com

Nicolas Bogler

Senior Manager, Investor Relations
+33 6 52 19 98 92
nicolas.bogler@ipsen.com

All growth rates are at constant exchange rates. ¹ Fully diluted.